Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Karyopharm Therapeutics (KPTI) and Simulations Plus (SLP)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Idexx Laboratories (IDXX – Research Report), Karyopharm Therapeutics (KPTI – Research Report) and Simulations Plus (SLP – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Idexx Laboratories (IDXX)
Piper Sandler analyst David Westenberg maintained a Hold rating on Idexx Laboratories today and set a price target of $775.00. The company’s shares closed last Wednesday at $696.46.
According to TipRanks.com, Westenberg is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Idexx Laboratories with a $792.78 average price target.
See the top stocks recommended by analysts >>
Karyopharm Therapeutics (KPTI)
H.C. Wainwright analyst Robert Burns maintained a Buy rating on Karyopharm Therapeutics yesterday and set a price target of $15.00. The company’s shares closed last Wednesday at $6.32, close to its 52-week low of $4.05.
According to TipRanks.com, Burns is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Karyopharm Therapeutics with a $15.00 average price target, which is a 151.7% upside from current levels. In a report issued on January 8, RBC Capital also maintained a Buy rating on the stock with a $19.00 price target.
Simulations Plus (SLP)
William Blair analyst Max Smock reiterated a Buy rating on Simulations Plus today. The company’s shares closed last Wednesday at $20.43.
According to TipRanks.com, Smock is a 3-star analyst with an average return of
Simulations Plus has an analyst consensus of Moderate Buy, with a price target consensus of $19.00, a -6.9% downside from current levels. In a report issued on January 8, Craig-Hallum also maintained a Buy rating on the stock.
